mRNA is no longer just a headline, it’s transforming medicine. From BioNTech’s acquisition of CureVac to the EMA’s and MHRA’s latest guidance on mRNA product development, and even the world’s first personalised CRISPR therapy for Baby KJ, the field has reached a new level of stability while opening doors to revolutionary therapeutic and gene editing applications.
Returning for its fifth year, the mRNA-Based Therapeutics Summit Europe gives you the insights and connections to turn these breakthroughs into action. The new Gene Editing Focus Day highlights how mRNA enables safer, transient editing strategies, while addressing regulatory and translational challenges. Hear directly from Moderna, AstraZeneca, CybernaX Bio, Avocet Bio, and others about clinical readiness and delivery innovations bringing therapies closer to patients.
With exclusive investor presentations and a high-profile panel featuring Innosuisse, NRW.Bank, and Lukasiewicz-PORT, you’ll gain candid perspectives on what makes an mRNA platform fundable in 2026, and actionable strategies to de-risk your programs and secure partnerships in today’s competitive landscape.
👨👧👦 Social Networks
💸 Website & Tickets
Go to Event Website
Drug Developer Pricing - Conference and Focus Day: EUR 3797.00, Drug Developer Pricing - Conference Only: EUR 2799.00, Academic Pricing - Conference and Focus Day: EUR 3197.00, Academic Pricing - Conference Only: EUR 2399.00, Service Provider Pricing - Conference and Focus Day: EUR 4697.00, Service Provider Pricing - Conference Only: EUR 3499.00
Advertisements